ACASTI PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.9 USD | -0.97% |
|
+1.05% | +0.35% |
| Feb. 12 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Feb. 07 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the Acasti Phar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Companyâs clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Sector
Pharmaceuticals
Calendar
2024-06-17
- Q4 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.97
CAD
Average target price
8.063
CAD
Spread / Average Target
+103.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.35% | 27.26M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ACST Stock
- News Acasti Pharma Inc.
- Transcript : Acasti Pharma Inc. - Special Call
